Press Releases April 13, 2026 08:00 PM

LeMaitre Will Announce First Quarter 2026 Earnings Results on May 5, 2026

LeMaitre Vascular to release Q1 2026 earnings and host conference call on May 5, 2026

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
LMAT

LeMaitre Vascular, a medical device company specializing in vascular implants and disposables, announced it will report its Q1 2026 financial results after market close on May 5, 2026. The company will also hold a conference call to discuss financials, business highlights, and outlook.

LeMaitre Will Announce First Quarter 2026 Earnings Results on May 5, 2026
LMAT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • LeMaitre Vascular focuses on devices and implants for peripheral vascular disease treatment, addressing a large patient population globally.
  • The Q1 2026 earnings release and conference call are scheduled for May 5, 2026, following market close.
  • The company targets vascular surgeons as its primary customers with specialized disposable and implantable products.

BURLINGTON, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.

Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay at ir.lemaitre.com.

About LeMaitre

LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com.

LeMaitre and the LeMaitre logo are registered trademarks of LeMaitre Vascular, Inc.


Risks

  • Financial results might not meet market expectations, leading to stock price volatility.
  • Healthcare regulations and reimbursement policies could impact product demand and company growth.
  • Competition in the vascular device market may exert pressure on market share and margins.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026